Stay updated on Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial

Sign up to get notified when there's something new on the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The revision tag on the page was updated to v3.5.0, replacing the previous v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-21T08:54:02.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Added official results data and expanded safety/efficacy endpoints for core and extension phases, including ADCOMS, CDR-SB, ADAS-Cog, CSF biomarkers, MRI volumetrics, and amyloid PET measures; TEAEs/SAEs definitions and the Results First Posted date are now included.
    Difference
    2%
    Check dated 2026-03-06T21:03:51.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.1 to v3.4.2 with no substantive content changes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T12:37:41.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    A new revision tag v3.4.1 was added and the previous v3.4.0 tag removed. No visible changes to core study content or functionality.
    Difference
    0.0%
    Check dated 2026-02-05T23:52:35.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    Revision: v3.3.4 has been added, replacing Revision: v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-15T04:27:17.000Z thumbnail image
  8. Check
    100 days ago
    Change Detected
    Summary
    Expanded the study locations to include numerous sites across the United States, Canada, and Europe (e.g., Alabama, Arizona, California; Ontario, Quebec; Paris; Berlin; etc.). It clarifies where recruitment and participation are possible.
    Difference
    2%
    Check dated 2025-12-24T14:16:31.000Z thumbnail image

Stay in the know with updates to Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page.